An infectious disease expert who led one of the largest clinical trials under Operation Warp Speed and served as protocol chair for the ACTIV-2 study, which tested antibodies and experimental therapeutics for mild and moderate COVID-19.

A leading researcher focused on RNA viruses posing pandemic threats, leveraging cutting-edge technologies to study virus-host interactions and innate immunity.

A medicinal chemist with expertise in respiratory and infectious diseases, driving the development of multiple clinical candidates for global health challenges.

A pharmaceutical industry leader with extensive C-suite experience overseeing clinical trials and scaling organizations in public biotech companies.

A pioneer in influenza research, serving as Director of the Global Health and Emerging Pathogens Institute, with over 480 publications advancing the understanding of viral replication.

Leads a laboratory established to counteract and prepare for pandemic-level viral threats, focusing on resistance-refractory antivirals and synergistic drug combinations.

A biotech executive specializing in genetic therapies, with experience managing strategic partnerships and advancing groundbreaking research in gene correction and molecular biology.

A drug development innovator with over 40 years of experience, advancing six clinical-stage compounds and contributing to 97 patents in medicinal chemistry and pharmacology.

An expert in preclinical development and pharmacokinetics, contributing to the advancement of rare and infectious disease treatments, including the successful acquisition of Bikam Pharmaceuticals.